The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Mechanistic Basis of Enzyme-Targeted Drugs
Abstract
Enzymes offer unique opportunities for drug design that are not available to cell surface receptors, nuclear hormone receptors, ion channels, transporters, and DNA. Here, we review the variety of inhibition mechanisms for enzyme-targeted drugs, and establish an enzyme target database for drugs currently marketed in the United States. From an analysis of the FDA Orange Book, there are 317 marketed drugs that work by inhibiting an enzyme. These drugs inhibit 71 enzymes, including 48 human, 13 bacterial, five viral, four fungal, and one protozoal enzyme. Among the 317 drugs, 65% either undergo reactive chemistry in the active site of the target enzyme or contain a structural motif related to the substrate. Among the 71 enzyme targets, 25 are irreversibly inhibited by drugs, and 19 of the 25 irreversibly inhibited enzymes are covalently modified by the drug. In two additional cases, the drug forms a covalent complex with the substrate, and in three more cases, the drug traps a covalent enzyme-substrate intermediate. Four of the 71 enzymes are inhibited by transition-state analogues. Moreover, advanced methods for determining transition-state structure now offer the opportunity for direct drug design without resorting to expensive random testing campaigns. A full appreciation of enzyme mechanisms sets enzymes apart as a specialized class of targets for highly directed drug design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331702 · Cited by 616
Research works printed but not linked: 158
- International Human Genome Sequence Consortium, 2004, Nature 431, 931−945.
- Drews J., 2000, Science 287
- Center for Drug Evaluation and Research, 2002, New Molecular Entities (NMEs) Reports
- Oneil M. J., 2001, The Merck Index
- Hardman J. G., 2001, Goodman & Gilman's The Pharmacological Basis of Therapeutics
- DiPiro J. T., 2002, Pharmacotherapy: A Pathophysiologic Approach
- McEvoy G. K., 2002, AHFS Drug Information
- Center for Drug Evaluation and Research, 2003, Electronic Orange Book
- Tipper D. J., 1965, Proc. Natl. Acad. Sci. U.S.A. 54
- Istvan E. S., 2001, Science 292, 1160−1164.
- Lienhard G. E., 1973, Science 180, 149−154.
- Wolfenden R., 1976, Rev. Biophys. Bioeng., 5, 10.1146/annurev.bb.05.060176.001415 · DOI · Paper page
- Radzicka A., 1995, Methods Enzymol. 249, 284−312.
- Agarwal R. P., 1977, Biochem. Pharmacol. 26, 359−367.
- Cushman D. W., 1987, J. Cardiovasc. Pharmacol., 10, 10.1097/00005344-198706107-00004 · DOI
- Byers L. D., 1973, Biochemistry 12
- Roberts N. A., 1990, Science 248, 358−361.
- Chong A. K., 1992, Eur. J. Biochem., 207, 10.1111/j.1432-1033.1992.tb17055.x · DOI · Paper page
- von Iztstein M., 1993, Nature 363, 418−423.
- Schramm V. L., 2005, Arch. Biochem. Biophys., 433, 26, 10.1016/j.abb.2004.08.035 · DOI
- Evans G. B., 2004, J. Med. Chem., 47, 10.1021/jm0306475 · doi:10.1021/jm0306475
- Lu W. P., 2001, J. Biol. Chem., 276
- Goffin C., 1998, Microbiol. Mol. Biol. Rev., 62, 10.1128/MMBR.62.4.1079-1093.1998 · DOI · Paper page
- Christensen H., 1990, Biochem. J., 266
- Kahan F. M., 1974, Ann. N.Y. Acad. Sci. 235, 364−386.
- Thomas A. M., 2004, Eur. J. Biochem., 271, 10.1111/j.1432-1033.2004.04196.x · doi:10.1111/j.1432-1033.2004.04196.x
- Hemler M., 1976, J. Biol. Chem., 251, 10.1016/S0021-9258(17)33098-3 · DOI · Paper page
- Van Der Ouderaa F. J., 1980, Eur. J. Biochem., 109, 8
- Siiteri P. K., 1975, J. Steroid Biochem., 6, 10.1016/0022-4731(75)90149-1 · DOI · Paper page
- Brueggemeier R. W., 2001, Am. J. Ther., 8, 10.1097/00045391-200109000-00007 · DOI
- Finberg J. P., 1983, Neuropharmacology 22, 441−446.
- Fowler C. J., 1982, Biochem. Pharmacol. 31, 3555−3561.
- Santi D. V., 1974, Biochemistry 13, 471−481.
- Poulin R., 1992, J. Biol. Chem., 267, 10.1016/S0021-9258(18)48472-4 · DOI · Paper page
- Grishin N. V., 1999, Biochemistry 38, 15174−15184.
- Wang E., 1978, Biochemistry 17, 1313−1321.
- Fenn T. D., 2003, Biochemistry 42, 5775−5783.
- Richardson P., 1998, Drugs 56, 307−335.
- Hadvary P., 1991, J. Biol. Chem., 266, 10.1016/S0021-9258(18)52203-1 · DOI · Paper page
- Winkler F. K., 1990, Nature 343, 771−774.
- Baker C. H., 1991, J. Med. Chem., 34, 10.1021/jm00110a019 · DOI · Paper page
- Nagasaka A., 1976, J. Clin. Endocrinol. Metab., 43, 10.1210/jcem-43-1-152 · doi:10.1210/jcem-43-1-152
- Engler H., 1983, Endocrinology, 112, 95, 10.1210/endo-112-1-86 · DOI
- Kohrle J., 1999, Mol. Cell. Endocrinol. 151, 103−119.
- Berry M. J., 1991, J. Biol. Chem., 266
- Yamada T., 1981, J. Endocrinol. Invest., 4, 10.1007/BF03348299 · DOI
- Kitson T. M., 1975, Biochem. J., 151, 10.1042/bj1510407 · DOI
- Tomlinson A. J., 1997, Biochem. Pharmacol. 54, 1253−1260.
- Shen M. L., 2001, Biochem. Pharmacol. 61, 537−545.
- Jin L., 1997, Proc. Natl. Acad. Sci. U.S.A. 94
- Hoylaerts M., 1984, J. Biol. Chem., 259, 10.1016/S0021-9258(18)91066-5 · DOI
- Rezaie A. R., 2000, Biochemistry 39, 12083−12090.
- Braun P. J., 1988, Biochemistry 27, 6517−6522.
- Holme E., 1998, J. Inherited Metab. Dis., 21
- Kavana M., 2003, Biochemistry 42, 10238−10245.
- Fasco M. J., 1983, Biochemistry 22, 5655−5660.
- Fasco M. J., 1982, J. Biol. Chem., 257
- Hughes J., 1980, Biochem. J., 191, 10.1042/bj1910209 · DOI
- Pope A. J., 1998, J. Biol. Chem., 273
- Furman P. A., 1984, J. Biol. Chem., 259, 10.1016/S0021-9258(17)42739-6 · DOI · Paper page
- Bull H. G., 1996, J. Am. Chem. Soc., 118
- Rozwarski D. A., 1998, Science, 279, 102, 10.1126/science.279.5347.98 · DOI · Paper page
- Quemard A., 1996, J. Am. Chem. Soc., 118, 10.1021/ja950998b · DOI
- Harrison R., 2002, Structure and function of xanthine oxidoreductase: Where are we now? Free Radical Biol. Med. 33, 774−797
- Silverman R. B., 1992, The Organic Chemistry of Drug Design and Drug Action
- Massey V., 1970, J. Biol. Chem., 245
- Spector T., 1970, J. Biol. Chem., 245, 10.1016/S0021-9258(18)62820-0 · DOI
- Sintchak M. D., 2000, Immunopharmacology 47, 163−184.
- Fleming M. A., 1996, Biochemistry 35, 6990−6997.
- Drlica K., 1997, Microbiol. Mol. Biol. Rev., 61
- Higgins P. G., 2003, Curr. Drug Targets 4, 181−190.
- Osheroff N., 1989, Pharmacol. Ther. 41, 223−241.
- Redinbo M. R., 1998, Science 279, 1504−1513.
- Fan Y., 1998, J. Med. Chem., 41
- Sander M., 1983, J. Biol. Chem., 258
- Wigley D. B., 1996, Structure 4, 117−120.
- Yang W., 2003, Med. Res. Rev., 23
- Kaplan A. P., 1991, Biochemistry 30, 8165−8170.
- Adams J., 2002, Oncologist, 7, 16, 10.1634/theoncologist.7-1-9 · DOI · Paper page
- Palombella V. J., 1998, Proc. Natl. Acad. Sci. U.S.A. 95
- Spence R. A., 1995, Science 267, 988−993.
- Grimsby J., 2003, Science 301, 370−373.
- Glaser B., 1998, N. Engl. J. Med., 338
- Christesen H. B., 2002, Diabetes 51, 1240−1246.
- Lee H., 2003, Biochemistry 42, 14711−14719.
- Feldmesser M., 2000, J. Infect. Dis., 182, 10.1086/317614 · DOI
- Coirini H., 2003, J. Neurochem., 84, 10.1046/j.1471-4159.2003.01512.x · DOI
- Corbin J. D., 1999, J. Biol. Chem., 274, 10.1074/jbc.274.20.13729 · DOI · Paper page
- Londesborough J., 1977, Biochem. J., 163, 10.1042/bj1630467 · doi:10.1042/bj1630467
- Hall M. G., 2001, Br. J. Clin. Pharmacol., 52
- Andriole G., 2004, J. Urol., 172
- Jann M. W., 2002, Clin. Pharmacokinet. 41, 719−739.
- Merkler D. J., 1990, Biochemistry 29, 8358−8364.
- Mustata G. I., 2003, Biopolymers 70, 186−200.
- Plapp B. V., 1984, Arch. Biochem. Biophys., 230, 38, 10.1016/0003-9861(84)90083-3 · doi:10.1016/0003-9861(84)90083-3
- Lipsky J. J., 2001, Chem.-Biol. Interact. 130−132, 93−102.
- Ferey-Roux G., 1998, Biochim. Biophys. Acta, 1388, 20, 10.1016/S0167-4838(98)00147-2 · DOI
- Sels J. P., 1999, Expert Opin. Pharmacother. 1, 149−156.
- Mallinger A. G., 1991, Psychopharmacol. Bull. 27, 493−502.
- Belanger A. E., 1996, Proc. Natl. Acad. Sci. U.S.A. 93
- Bell R. L., 1992, Int. J. Immunopharmacol., 14
- Burkhard P., 2001, Nat. Struct. Biol. 8, 963−967.
- Livermore D. M., 1993, J. Antimicrob. Chemother. 31 (Suppl. A), 9−21.
- Wells J. W., 1975, J. Biol. Chem., 250, 10.1016/S0021-9258(19)41546-9 · DOI
- Kurth M. C., 1998, Neurology, 50, S14, 10.1212/WNL.50.5_Suppl_5.S3 · doi:10.1212/wnl.50.5_suppl_5.s3
- Platt F. M., 1994, J. Biol. Chem., 269
- Fan C., 1997, Biochemistry 36, 2531−2538.
- Williams J. W., 1979, Biochemistry 18, 2567−2573.
- McLean J. E., 2001, Biochemistry 40, 2194−2200.
- Baca A. M., 2000, J. Mol. Biol., 302
- Arun B., 2001, Expert Opin. Pharmacother. 2, 491−505.
- Anderson V. E., 2001, Curr. Pharm. Des. 7, 337−353.
- Villarreal E. C., 2001, Prog. Drug Res. Spec. No., 185−228.
- Campbell E. A., 2001, Cell 104, 901−912.
- Stone K. J., 1971, Proc. Natl. Acad. Sci. U.S.A. 68
- Vilcheze C., 2000, J. Bacteriol., 182, 10.1128/JB.182.14.4059-4067.2000 · DOI · Paper page
- Kiefel M. J., 1999, Prog. Med. Chem., 36, 28
- Keam S. J., 2002, Drugs 62, 1673−1685
- Bergstrom J. D., 2000, Arch. Biochem. Biophys. 373, 231−241.
- Zimhony O., 2000, 6, 1043−1047.
- Samulitis B. K., 1987, Drugs Exp. Clin. Res. 13, 517−524.
- Phiel C. J., 2001, J. Biol. Chem., 276
- Rodriguez-Barrios F., 2004, Chem. 4, 991−1007.
- Sachs G., 1995, Rev. Pharmacol. Toxicol., 35
- Istvan E. S., 2002, Am. Heart J., 144, 10.1067/mhj.2002.130300 · DOI
- Sintchak M. D., 1996, Cell 85, 921−930.
- Engler H., 1982, Biochem. Pharmacol. 31, 3801−3806.
- Brown M. J., 2000, Biochemistry 39, 6003−6011.
- Campbell B. J., 1984, J. Biol. Chem., 259
- Bacchi C. J., 1980, Science 210, 332−334.
- Fyfe J. A., 1973, J. Biol. Chem., 248
- Cushman D. W., 1982, Am. J. Cardiol., 49, 10.1016/0002-9149(82)90348-4 · DOI
- Mendelsohn L. G., 1996, Invest. New Drugs 14, 287−294.
- Scott C. F., 1987, Blood 69, 1431−1436.
- Markus G., 1978, J. Biol. Chem., 253
- Gierse J. K., 1996, J. Biol. Chem., 271, 10.1074/jbc.271.26.15810 · DOI · Paper page
- Adams J., 1999, Cancer Res. 59, 2615−2622.
- Schindler T., 2000, Science 289
- Silva D. J., 1998, Biochemistry 37, 5528−5535.
- Maag D., 2001, J. Biol. Chem., 276, 10.1074/jbc.C100349200 · DOI · Paper page
- Sluis-Cremer N., 2004, Curr. HIV Res. 2, 323−332.
- Lee W., 2001, Proc. Natl. Acad. Sci. U.S.A. 98
- Smith T. W., 1989, Therapie 44, 431−435.
- Favre B., 1997, Arch. Biochem. Biophys. 340, 265−269.
- Yoshida Y., 1987, Biochem. Pharmacol. 36, 229−235.
- Lembcke B., 1985, Digestion 31, 120−127.
- Rydel, T. J., Ravichandran, K. G., Tulinsky, A., Bode, W., Huber, R., Roitsch, C., and Fenton, J. W., II (1990) The structure of a complex of recombinant hirudin and human α-thrombin, Science 249 , 277−280. · DOI · Paper page
- Matthews D. A., 1989, Adv. Enzyme Regul., 29, 60, 10.1016/0065-2571(89)90093-9 · doi:10.1016/0065-2571(89)90093-9
- Toyoda N., 1997, Endocrinology 138, 213−219.
- Lookene A., 1994, Eur. J. Biochem., 222, 10.1111/j.1432-1033.1994.tb18878.x · DOI
- Fitzpatrick P. F., 1991, Biochemistry 30, 3658−3662.
- Skarzynski T., 1996, Structure 4, 1465−1474.
- Johnston J. O., 1998, Crit. Rev. Biochem. Mol. Biol., 33
- Pearson M. A., 1997, Biochemistry 36, 8164−8172.
- Rost S., 2004, Nature 427, 537−541.
- Cha S., 1975, Biochem. Pharmacol. 24, 2187−2197.
- Singh V., 2005, J. Biol. Chem. (in press).
- Abbreviations FDA, Food and Drug Administration
Cited by
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Mechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X., & Chen, Y. Z. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 969
Drugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
Mechanism-Based Profiling of Enzyme Families
Evans, M. J., & Cravatt, B. F. (2006) · Chemical Reviews · doi:10.1021/cr050288g · Cited by 564
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534
Szabo, C., & Papapetropoulos, A. (2017) · Pharmacological Reviews · doi:10.1124/pr.117.014050 · Cited by 423
A Perspective on the Kinetics of Covalent and Irreversible Inhibition
Strelow, J. M. (2017) · SLAS Discovery · doi:10.1177/1087057116671509 · Cited by 392
Strategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors
Johnson, D. S., Weerapana, E., & Cravatt, B. F. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.21 · Cited by 387
Covalent Modifiers: An Orthogonal Approach to Drug Design
Potashman, M. H., & Duggan, M. E. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8008597 · Cited by 346
Towards third generation matrix metalloproteinase inhibitors for cancer therapy
Overall, C. M., & Kleifeld, O. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603043 · Cited by 340
Covalent inhibitors design and discovery.
De Cesco, S., Kurian, J., Dufresne, C., Mittermaier, A. K., & Moitessier, N. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.019 · Cited by 315
Covalent docking of large libraries for the discovery of chemical probes
London, N., Miller, R. M., Krishnan, S., Uchida, K., Irwin, J. J., Eidam, O., Gibold, L., Cimermančič, P., Bonnet, R., Shoichet, B. K., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1666 · Cited by 274
Smith, A. J. T., Zhang, X., Leach, A. G., & Houk, K. N. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800498e · Cited by 193
Keap Calm, and Carry on Covalently
Wilson, A. J., Kerns, J. K., Callahan, J. F., & Moody, C. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400224q · Cited by 171
Theory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls
Kumalo, H., Bhakat, S., & Soliman, M. (2015) · Molecules · doi:10.3390/molecules20021984 · Cited by 158
The Design of Covalent Allosteric Drugs
Nussinov, R., & Tsai, C.-J. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124401 · Cited by 112
New Electrophiles and Strategies for Mechanism-Based and Targeted Covalent Inhibitor Design
Ray, S., & Murkin, A. S. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00293 · Cited by 108
Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine
Hagel, M., Niu, D., St Martin, T., Sheets, M. P., Qiao, L., Bernard, H., Karp, R. M., Zhu, Z., Labenski, M. T., Chaturvedi, P., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.492 · Cited by 95
Metadata
- Authors
- Robertson, J. G.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2005-03-22
- Volume
- 44
- Issue
- 15
- Pages
- 5561-5571
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2004519217
- Cited by
- 248
- References
- 1
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.